New hope for kids with tough cancers: experimental 'Living Drug' trial opens
NCT ID NCT06508931
Summary
This study is testing an experimental CAR-T cell therapy called MB-CART2019.1 in children and teenagers (6 months to under 18 years old) whose aggressive B-cell cancers have come back or have not responded to at least one prior treatment. The main goals are to see if the treatment is safe and if it can shrink or eliminate the cancer. Participants will receive a single infusion of their own genetically modified immune cells after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.